KURA Q4 2024 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M

Gross Profit

$54M100.0% margin

Operating Income

-$22M-41.7% margin

Net Income

-$19M-35.7% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$269M

Free Cash Flow

$269M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$760M

Total Liabilities

$347M

Stockholders' Equity

$414M

Cash & Equivalents

$224M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$0	—
Gross Profit	$54M	-$214,000	+25279.0%
Operating Income	-$22M	-$47M	+52.0%
Net Income	-$19M	-$43M	+55.1%